RAD51 and neoplasm: To capitalize upon the potential of PARPi treatment in these settings, a number of methods have been explored to detect tumor BRCAness and predict PARPi sensitivity, including panel sequencing for DNA repair gene mutations, repair gene expression microarrays, testing for surrogate markers of HR deficiency such as loss of heterozygosity or sequence deletions associated with junctional microhomology, or functional tests of repair capacity such as RAD51 foci formation (recently reviewed in [21]).